TY - JOUR

T1 - Diagnostik og behandling af maturity onset diabetes of the young type 3

AU - Rose, Kathrine

AU - Christensen, Alexander Sidelmann

AU - Storgaard, Heidi

AU - Hædersdal, Sofie

AU - Hansen, Torben

AU - Knop, Filip Krag

AU - Vilsbøll, Tina

PY - 2018

Y1 - 2018

N2 - Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.

AB - Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.

KW - Diabetes Mellitus, Type 2/diagnosis

KW - Humans

KW - Hypoglycemic Agents/therapeutic use

KW - Insulin-Secreting Cells/metabolism

KW - Sulfonylurea Compounds/therapeutic use

M3 - Tidsskriftartikel

C2 - 29429476

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V06170502

ER -